비침습적 간섬유화 측정기(Fibroscan)의 기술적 개요와 한의임상적 유용성 고찰
The Technological Concept of Fibroscan and its Clinical Usefulness in the Traditional Korean Medical Field
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: The liver fibroscan has been developed as a noninvasive and convenient method to assess hepatic fibrosis. This study aimed to review this device in terms of its technological concept and clinical application in traditional Korean medicine (TKM). Methods: The technological background, diagnostic evaluation, and clinical usefulness of fibroscan were reviewed using various literature and clinical studies. One clinical example-a patient with hepatofibrosis who had been treated with TKM-is presented. Results: The liver fibroscan was approved as a medical device for noninvasive measurement of the hepatic fibrosis level by the Korean Food and Drug Administration (KFDA). Numerous clinical studies have confirmed that its sensitivity and specificity allow it to serve as a substitute for liver biopsy, the present gold standard diagnostic method. The accuracy and reproducibility and lack of technical risks are strong points of the fibroscan; however, it has some limitations for application, especially in patients with obesity or severe hepatitis. One clinical example showed the applicability of the liver fibroscan in herbal medicine-based treatments. Conclusions: The requirement for diagnostic medical devices is an important issue in TKM; therefore, this study provides valuable information for practitioners of TKM.
Abstract
Objectives: The liver fibroscan has been developed as a noninvasive and convenient method to assess hepatic fibrosis. This study aimed to review this device in terms of its technological concept and clinical application in traditional Korean medicine (TKM). Methods: The technological background, diagnostic evaluation, and clinical usefulness of fibroscan were reviewed using various literature and clinical studies. One clinical example-a patient with hepatofibrosis who had been treated with TKM-is presented. Results: The liver fibroscan was approved as a medical device for noninvasive measurement of the hepatic fibrosis level by the Korean Food and Drug Administration (KFDA). Numerous clinical studies have confirmed that its sensitivity and specificity allow it to serve as a substitute for liver biopsy, the present gold standard diagnostic method. The accuracy and reproducibility and lack of technical risks are strong points of the fibroscan; however, it has some limitations for application, especially in patients with obesity or severe hepatitis. One clinical example showed the applicability of the liver fibroscan in herbal medicine-based treatments. Conclusions: The requirement for diagnostic medical devices is an important issue in TKM; therefore, this study provides valuable information for practitioners of TKM.
참고문헌 (42)
- 김혁, "Recent trends in hepatitis B virus infection in the general Korean population", The Korean Journal of Internal Medicine, 28(4), pp.413~419 (2013), 대한내과학회[DOI]
- Kocabayoglu P, "Cellular basis of hepatic fibrosis and its role in inflammation and cancer", Front Biosci (Schol Ed), 5, pp.217~230 (2013)
- Schmeltzer PA, "Noninvasive tools to assess hepatic fibrosis: ready for prime time?", Gastroenterol Clin North Am, 40(3), pp.507~521 (2011)
- Bravo AA, "Liver biopsy", N Engl J Med, 344(7), pp.495~500 (2001)
- Trifan A, "Checkmate to liver biopsy in chronic hepatitis C?", World J Gastroenterol, 18(39), pp.5514~5520 (2012)
- Bedossa P, "Sampling variability of liver fibrosis in chronic hepatitis C", Hepatology, 38(6), pp.1449~1457 (2003)
- Papastergiou V, "Non-invasive assessment of liver fibrosis", Ann Gastroenterol, 25(3), pp.218~231 (2012)
- Wong GL, "Update of liver fibrosis and steatosis with transient elastography (Fibroscan)", Gastroenterol Rep (Oxf), 1(1), pp.19~26 (2013)
- Lee MH, "Comparison of surrogate serum markers and transient elastography (Fibroscan)for assessing cirrhosis in patients with chronic viral hepatitis", Dig Dis Sci, 55(12), pp.3552~3560 (2010)
- Afdhal NH, "Fibroscan (transient elastography)for the measurement of liver fibrosis", Gastroenterol Hepatol (NY), 8(9), pp.605~607 (2012)
- Kemp W, "FibroScan® and transient elastography", Aust Fam Physician, 42(7), pp.468~471 (2013)
- Pinzani M, "Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography", Nat Clin Pract Gastroenterol Hepatol, 5(2), pp.95~106 (2008)
- Deffieux T, "Investigating liver stiffness and viscosity for fibrosis, steatosis and activity staging using Shear Wave Elastography", J Hepatol, 62(2), pp.317~324 (2015)
- Sandrin L, "The role of the coupling term in transient elastography", J Acoust Soc Am, 115(1), pp.73~83 (2004)
- 배락천, "만성 간질환 환자에서 순간탄성측정법(transient elastography, FibroscanⓇ)에 의한 간탄력도에 영향을 줄 수 있는 임상요소", Clinical and Molecular Hepatology, 16(2), pp.123~130 (2010), 대한간학회
- Shaheen AA, "FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy", Am J Gastroenterol, 102(11), pp.2589~2600 (2007)
- Boursier J, "A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C", Am J Gastroenterol, 106(7), pp.1255~1263 (2011)
- Goyal R, "Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B", J Gastroenterol Hepatol, 28(11), pp.1738~1745 (2013)
- Kim SU, "Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B", Aliment Pharmacol Ther, 32(3), pp.498~505 (2010)
- Nguyen-Khac E, "Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests", Aliment Pharmacol Ther, 28(10), pp.1188~1198 (2008)
- Cocciolillo S, "CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis", World J Hepatol, 6(7), pp.496~503 (2014)
- Theise ND, "Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach", Mod Pathol, 20(Suppl 1), pp.S3~S14 (2007)
- Kim SU, "The usefulness of liver stiffness measurement using FibroScan in chronic hepatitis C in South Korea: a multicenter, prospective study", J Gastroenterol Hepatol, 26(1), pp.171~178 (2011)
- Goertz RS, "Impact of food intake, ultrasound transducer, breathing maneuvers and body position on acoustic radiation force impulse (ARFI) elastometry of the liver", Ultraschall Med, 33, pp.380~385 (2012)
- Popescu A, "The influence of food intake on liver stiffness values assessed by acoustic radiation force impulse elastography-preliminary results", Ultrasound Med Biol, 39, pp.579~584 (2013)
- Myers RP, "Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy", Liver Int, 30(10), pp.1471~1480 (2010)
- Ji D, "The frequency and determinants of liver stiffness measurement failure: a retrospective study of “real-life" 38,464 examinations", PLoS One, 9(8), pp.e105183~ (2014)
- Herrero JI, "Comparison of the M and XL FibroScan(®) probes to estimate liver stiffness by transient elastography", Gastroenterol Hepatol, 37(4), pp.233~239 (2014)
- Ding H, "Noninvasive measurement of liver fibrosis by transient elastography and influencing factors in patients with chronic hepatitis B-A single center retrospective study of 466 patients", J Huazhong Univ Sci Technolog Med Sci, 32(1), pp.69~74 (2012)
- Boursier J, "Reproducibility of liver stiffness measurement by ultrasonographic elastometry", Clin Gastroenterol Hepatol, 6(11), pp.1263~1269 (2008)
- Kim SU, "Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B", Aliment Pharmacol Ther, 32(3), pp.498~505 (2010)
- Wong VW, "Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease", Hepatology, 51(2), pp.454~462 (2009)
- Ginès P1, "Management of cirrhosis and ascites", N Engl J Med, 350(16), pp.1646~1654 (2004)
- Friedman SL, "Liver fibrosis -from bench to bedside", J Hepatol, 38(Suppl 1), pp.S38~S53 (2003)
- Castera L, "How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?", Liver Int, 31(Suppl 1), pp.13~17 (2011)
- Geramizadeh B, "Serum hyaluronic acid as a noninvasive marker of hepatic fibrosis in chronic hepatitis B", Saudi J Gastroenterol, 14(4), pp.174~177 (2008)
- Bonder A, "Utilization of FibroScan in clinical practice", Curr Gastroenterol Rep, 16(2), pp.372~ (2014)
- Schuppan D, "Evolving therapies for liver fibrosis", J Clin Invest, 123(5), pp.1887~1901 (2013)
- Yang L, "Effectiveness of the PPARγagonist, GW570, in liver fibrosis", Inflamm Res, 59(12), pp.1061~1071 (2010)
- Sookoian S, "Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study", World J Gastroenterol, 11(48), pp.7560~7563 (2005)